Heron Therapeutics (HRTX) Change in Receivables (2010 - 2026)

Heron Therapeutics (HRTX) has 12 years of Change in Receivables data on file, last reported at -$5.9 million in Q1 2026.

• Quarterly Change in Receivables fell 3964.83% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (down 63.05% YoY) and the FY2025 annual result came in at $10.7 million, down 42.88% from the prior year.
• Change in Receivables eased to -$5.9 million in Q1 2026, from $8.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $25.2 million in Q2 2023 to a low of -$12.9 million in Q3 2023.
• A 5-year average of $2.8 million and a median of $1.2 million in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables jumped 3255.62% — and 2026, when it plunged 3964.83%.
• Tracing HRTX's Change in Receivables over 5 years: stood at $9.9 million in 2022, then tumbled by 137.1% to -$3.7 million in 2023, then jumped by 423.73% to $11.8 million in 2024, then retreated by 27.88% to $8.5 million in 2025, then sank by 169.02% to -$5.9 million in 2026.
• The last three Change in Receivables figures came in at -$5.9 million (Q1 2026), $8.5 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.